OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. O'Reilly Discusses Advancements in Early-Stage Pancreatic Cancer

December 16th 2017

Eileen O’Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center, discusses advances for patients with early stage pancreatic cancer.

Dr. Mahantshetty Discusses Chemoradiation in Cervical Cancer

December 16th 2017

Umesh Mahantshetty, MD, MBBS, radiation oncologist, Tata Memorial Hospital, Mumbai, discusses chemoradiation in patients with cervical cancer.

Dr. Davids on Ibrutinib Plus FCR in Younger Patients With CLL

December 16th 2017

Matthew S. Davids, MD, MMSc, Associate Director, Dana-Farber Cancer Institute, Center for Chronic Lymphocytic Leukemia, discusses ibrutinib plus FCR in younger patients with CLL.

Dr. Oh Discusses Choosing Abiraterone in Prostate Cancer

December 14th 2017

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai School of Medicine, explains when he would choose abiraterone acetate (Zytiga) for patients with prostate cancer.

Dr. Tripathy Discusses Lurbinectedin in Breast Cancer

December 14th 2017

Debu Tripathy, MD, professor of medicine, chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses lurbinectedin (PM01183) for patients with breast cancer.

Dr. Herrera Discusses Polatuzumab Vedotin in DLBCL

December 14th 2017

Alex Herrera, MD, assistant professor, Department of Hematology and Hematologic Cell Transplantation, City of Hope, discusses polatuzumab vedotin in diffuse large B-cell lymphoma.

Dr. McDermott on Single-Agent Nivolumab in RCC

December 14th 2017

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses nivolumab (Opdivo) as a single-agent for the treatment of patients with renal cell carcinoma.

Dr. Karmali on the Impact of CAR T-Cell Therapy in DLBCL

December 14th 2017

Reem Karmali, MD, Feinberg School of Medicine, Northwestern University, discusses the impact of chimeric antigen receptor (CAR) T-cell therapy on the treatment of patients with diffuse large B-cell lymphoma (DLBCL).

Dr. Chari on Challenges in Sequencing Agents for Multiple Myeloma

December 14th 2017

Ajai Chari, MD, associate professor, Mount Sinai Hospital, discusses challenges in sequencing agents for patients with multiple myeloma.

Dr. Kemeny on Liver-Directed Therapy for Metastatic CRC

December 14th 2017

Nancy E. Kemeny, MD, a medical oncologist at Memorial Sloan Kettering Cancer Institute, discusses liver-directed therapies for patients with metastatic colorectal cancer (CRC).

Dr. King Discusses Lymph Node Resection in Breast Cancer

December 14th 2017

Tari King, MD, FACS, chief of Breast Surgery, Dana-Farber Cancer Institute, Brigham Women’s Cancer Center, discusses lymph node resection in breast cancer.

Dr. Landi on the Association Between Genetic Variance and Melanoma Risk

December 14th 2017

Maria Teresa Landi, MD, PhD, senior investigator, Integrative Tumor Epidemiology Branch, National Cancer Institute, discusses the association between genetic variance and melanoma risk.

Dr. Mileham Discusses Biomarkers in Lung Cancer

December 14th 2017

Kathryn Mileham, MD, medical oncologist, Levine Cancer Institute, Carolinas HealthCare System, discusses biomarkers in lung cancer.

Dr. Sweeney on Chemotherapy Versus Abiraterone for mCRPC

December 14th 2017

Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses the role of chemotherapy versus abiraterone (Zytiga) for patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Levine on Sequencing of Agents for Ovarian Cancer

December 14th 2017

Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone's Perlmutter Cancer Center, discusses the sequencing of agents for patients with ovarian cancer.

Dr. Diaz on Response Rates for MSI-H and NTRK Fusions in GI Cancer

December 13th 2017

Luis A. Diaz, MD, head of the division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses the responses seen with microsatellite-instability high (MSI-H) and NTRK fusions in patients with gastrointestinal cancer.

Dr. Saltz Discusses Chemotherapy in Metastatic CRC

December 12th 2017

Leonard Saltz, MD, Executive Director for Clinical Value & Sustainability, head, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center, discusses chemotherapy for patients with metastatic colorectal cancer.

Dr. Plimack on Second-Line Checkpoint Inhibitors in Bladder Cancer

December 12th 2017

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the approved checkpoint inhibitors for the second-line treatment of patients with bladder cancer.

Dr. Monk Discusses Immunotherapy in Ovarian Cancer

December 12th 2017

Bradley J. Monk, MD, FACOG, FACS, professor, director of the Division of Gynecologic Oncology at Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, Arizona, discusses immunotherapy for the treatment of patients with ovarian cancer.

Dr. McKay Discusses Immunotherapy Trials in RCC

December 12th 2017

Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy trials in renal cell carcinoma.